. 2022 Oct 12;36:103231. doi: 10.1016/j.nicl.2022.103231

Table 2.

$R_{2}^{*}$ values (s⁻¹) and $R_{2 (I S Q R)}^{*}$ values (s⁻¹) in each region of interest of PD group, PD subgroups and controls.

	All PD patients	Paired controls	Disease duration				Disease severity		P value
	All PD patients	Paired controls	PD patients G1	PD patients G2	PD patients G3	PD patients G4	PD patients (H&Y < 2)	PD patients (H&Y >= 2)
$R_{2}^{*}$ (raw data)
Number of subjects	98	65	31	26	26	15	28	70
SN_D	39.23 ± 5.85	34.94 ± 4.86	38.3 ± 4.53	39.48 ± 5.24	38.87 ± 7.71	41.96 ± 5.65	38.54 ± 4.89	39.51 ± 6.21	< 0.0001^a; 0.16^b; 0.75^c
SN_ND	38.88 ± 5.5	34.94 ± 4.86	37.29 ± 3.59	39.59 ± 5.63	39.63 ± 7.2	40.09 ± 5.18	38.28 ± 4.8	39.12 ± 5.77	< 0.0001^a; 0.37^b; 0.8 ^c
RN_D	33.42 ± 4.39	34.48 ± 4.83	33.35 ± 4	34.67 ± 4.82	32.75 ± 5.05	32.33 ± 2.46	34.75 ± 4.03	32.87 ± 4.44	0.14 ^a; 0.14^b; 0.06^c
RN_ND	33.51 ± 4.59	34.48 ± 4.83	33.84 ± 3.99	34.62 ± 5.31	32.35 ± 5.29	32.7 ± 1.92	34.13 ± 4.25	33.26 ± 4.72	0.19 ^a; 0.32^b; 0.42^c
GPi_D	28.64 ± 5.01	29.87 ± 4.72	29.57 ± 4.39	27.34 ± 4.15	28.67 ± 6.43	28.81 ± 4.99	28.39 ± 4.63	28.75 ± 5.19	0.1 ^a; 0.56^b; 0.79^c
GPi_ND	28.6 ± 4.4	29.86 ± 4.72	29.1 ± 4.36	28.06 ± 4.04	28.36 ± 4.93	28.89 ± 4.52	29.04 ± 4.57	28.43 ± 4.36	0.08 ^a; 0.74^b; 0.49^c
GPe_D	34.44 ± 4.22	35.3 ± 4.44	35.21 ± 3.44	34.32 ± 3.45	34.08 ± 5.51	33.33 ± 4.78	34.82 ± 3.98	34.29 ± 4.34	0.2 ^a; 0.75^b; 0.73^c
GPe_ND	34.76 ± 4.44	35.3 ± 4.44	34.89 ± 4.32	34.2 ± 3.33	35.25 ± 5.56	34.59 ± 4.63	35.18 ± 4.66	34.6 ± 4.37	0.44 ^a; 0.85^b; 0.88^c
STR_D	27.41 ± 3.21	28.46 ± 3.92	27.82 ± 2.92	27.54 ± 3.49	27.09 ± 3.63	26.7 ± 2.63	28.26 ± 2.98	27.07 ± 3.27	0.06 ^a; 0.81^b; 0.13^c
STR_ND	27.28 ± 3.06	28.46 ± 3.92	27.4 ± 3.08	27.49 ± 3.42	27.08 ± 2.75	26.96 ± 3.19	28.26 ± 3.07	26.88 ± 2.98	0.05 ^a; 0.92^b; 0.06^c
GM	20.1 ± 1.2	19.7 ± 1.3	–	–	–	–			0.03^a
WM	20.8 ± 0.8	20.5 ± 0.8	–	–	–	–			0.03^a

$R_{2 (I S Q R}^{*})$
SN_D	6.05 ± 5.34	0.46 ± 1.92	4.83 ± 4.42	4.91 ± 4.47	6.48 ± 6.63	9.82 ± 4.5	3.98 ± 3.89	6.88 ± 5.64	< 0.0001^a; 0.01^b; 0.02^c
SN_ND	5.36 ± 4.95	0.46 ± 1.92	3.44 ± 3.86	4.97 ± 4.53	7.28 ± 5.75	7.39 ± 5.03	4.14 ± 4.57	5.85 ± 5.05	< 0.0001^a; 0.03^b; 0.09^c
GPi_D	−4.77 ± 5.84	−4.06 ± 5.52	−3.78 ± 5.12	−7.33 ± 6.48	−4.09 ± 6.4	−3.53 ± 3.69	−6.37 ± 5.93	−4.12 ± 5.72	0.47 ^a; 0.17^b; 0.15^c
GPi_ND	−4.91 ± 6.02	−4.06 ± 5.52	−4.76 ± 5.09	−6.56 ± 7.14	−3.98 ± 6.47	−3.81 ± 4.72	−5.1 ± 6.29	−4.83 ± 5.95	0.35 ^a; 0.72^b; 0.8 ^c
GPe_D	1.02 ± 5.32	1.36 ± 4.6	1.86 ± 4.81	−0.35 ± 5.23	1.32 ± 6.52	1 ± 4.01	0.06 ± 5.64	1.41 ± 5.18	0.66 ^a; 0.38^b; 0.19^c
GPe_ND	1.25 ± 6.2	1.37 ± 4.61	1.04 ± 5.25	0.42 ± 6.67	2.89 ± 7.47	1.88 ± 4.12	1.04 ± 6.01	1.33 ± 6.32	0.89 ^a; 0.31^b; 0.84^c
STR_D	−6.01 ± 4.81	−5.48 ± 4.85	−5.52 ± 4.64	−7.13 ± 4.91	−5.67 ± 5.44	−5.63 ± 3.72	−6.5 ± 4.37	−5.8 ± 4.99	0.49 ^a; 0.69^b; 0.42^c
STR_ND	−6.23 ± 4.85	−5.48 ± 4.85	−6.44 ± 4.66	−7.13 ± 5.22	−5.28 ± 5.13	−5.74 ± 4.11	−5.87 ± 4.22	−6.37 ± 5.1	0.72 ^a; 0.8 ^b; 0.73^c

Values are expressed as Mean ± standard deviation; PD = Parkinson’s disease; na = not applicable; SN_D = substantia nigra_dominant; SN_ND = substantia nigra_non dominant; RN_D = red nucleus_dominant; RN_ND = red nucleus_non dominant; GPe = globus pallidus externus_dominant; GPe = globus pallidus externus_non dominant; GPi_D = globus pallidus internus_dominant; GPi_ND = globus pallidus internus_non dominant; STR_D = striatum_dominant; STR_ND = striatum_non dominant; GM = grey matter; WM = white matter. G1: Group1 < 5 years; G2: Group2 > 5 and ≤ 10 years; G3: Group3 > 10 and ≤ 15 years, G4: Group4 > 15 years.

: statistical significance between PD patients and healthy controls.

: statistical significance between the PD subgroups according to disease duration.

: statistical significance between the PD subgroups according to disease severity.